Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Lenalidomide induced response in a patient with follicular lymphoma of the skin and an anti-rituximab-antibody

Lenalidomide induced response in a patient with follicular lymphoma of the skin and an... case report memo (2013) 6:123–126 DOI 10.1007/s12254-013-0089-5 Lenalidomide induced response in a patient with follicular lymphoma of the skin and an anti-rituximab-antibody Cathrin Skrabs · Christian Sillaber · Ana-Iris Schiefer · Ingrid Simonitsch-Klupp · Thomas Staudinger · Monique Putman · Werner Rabitsch · Ulrich Jaeger Received: 20 March 2013 / Accepted: 21 May 2013 / Published online: 18 June 2013 © Springer-Verlag Wien 2013 Abstract meric antibodies against rituximab were verified in an Background Patients with follicular lymphoma ineligi- early stage of disease, rendering further use of the drug ble for standard treatment with the anti-CD20 antibody impossible. After five treatment lines he developed pro- rituximab represent a considerable challenge as they re- gressive follicular lymphoma with skin involvement, quire alternative therapeutic approaches. which was treated with lenalidomide monotherapy. Patient and methods We describe a patient who expe- Results Six cycles of lenalidomide monotherapy (25  mg rienced a severe episode of serum sickness. Antichi- orally for 21 days, 1 week off ) led to a very good partial response rendering the patient eligible for autologous stem cell transplantation. Data on efficacy of lenalido- U. Jaeger, MD () · C. Skrabs · C. Sillaber mide in follicular lymphoma are reviewed. Department of Medicine I, Division of Hematology http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png memo - Magazine of European Medical Oncology Springer Journals

Lenalidomide induced response in a patient with follicular lymphoma of the skin and an anti-rituximab-antibody

Loading next page...
 
/lp/springer-journals/lenalidomide-induced-response-in-a-patient-with-follicular-lymphoma-of-ET1sQt8hoC
Publisher
Springer Journals
Copyright
Copyright © 2013 by Springer-Verlag Wien
Subject
Medicine & Public Health; Oncology; Medicine/Public Health, general
ISSN
1865-5041
eISSN
1865-5076
DOI
10.1007/s12254-013-0089-5
Publisher site
See Article on Publisher Site

Abstract

case report memo (2013) 6:123–126 DOI 10.1007/s12254-013-0089-5 Lenalidomide induced response in a patient with follicular lymphoma of the skin and an anti-rituximab-antibody Cathrin Skrabs · Christian Sillaber · Ana-Iris Schiefer · Ingrid Simonitsch-Klupp · Thomas Staudinger · Monique Putman · Werner Rabitsch · Ulrich Jaeger Received: 20 March 2013 / Accepted: 21 May 2013 / Published online: 18 June 2013 © Springer-Verlag Wien 2013 Abstract meric antibodies against rituximab were verified in an Background Patients with follicular lymphoma ineligi- early stage of disease, rendering further use of the drug ble for standard treatment with the anti-CD20 antibody impossible. After five treatment lines he developed pro- rituximab represent a considerable challenge as they re- gressive follicular lymphoma with skin involvement, quire alternative therapeutic approaches. which was treated with lenalidomide monotherapy. Patient and methods We describe a patient who expe- Results Six cycles of lenalidomide monotherapy (25  mg rienced a severe episode of serum sickness. Antichi- orally for 21 days, 1 week off ) led to a very good partial response rendering the patient eligible for autologous stem cell transplantation. Data on efficacy of lenalido- U. Jaeger, MD () · C. Skrabs · C. Sillaber mide in follicular lymphoma are reviewed. Department of Medicine I, Division of Hematology

Journal

memo - Magazine of European Medical OncologySpringer Journals

Published: Jun 18, 2013

References